OmniScience Inc. and INmune Bio Inc. Partner to Accelerate a Phase 2 Alzheimers Trial with ...
| INMB Stock | USD 9.22 0.16 1.77% |
About 56% of all INmune Bio's investors are looking to take a long position. The analysis of the overall investor sentiment regarding INmune Bio suggests that some traders are interested. The current market sentiment, together with INmune Bio's historical and current headlines, can help investors time the market. In addition, many technical investors use INmune Bio stock news signals to limit their universe of possible portfolio assets.
INmune |
Vivo Empowers Clinical Development Teams to Accelerate Decision-making and Analyses in Clinical Trials for Improved Outcomes HOUSTON and BOCA RATON, Fla., Dec.
Read at gurufocus.com
 |
INmune Bio Fundamental Analysis
We analyze INmune Bio's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of INmune Bio using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of INmune Bio based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Shares Owned By Institutions
Shares Owned By Institutions Comparative Analysis
INmune Bio is currently under evaluation in shares owned by institutions category among its peers. Shares Owned by Institutions show the percentage of the outstanding shares of stock issued by a company that is currently owned by other institutions such as asset management firms, hedge funds, or investment banks. Many investors like investing in companies with a large percentage of the firm owned by institutions because they believe that larger firms such as banks, pension funds, and mutual funds, will invest when they think that good things are going to happen.
INmune Bio Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with INmune Bio stock to make a market-neutral strategy. Peer analysis of INmune Bio could also be used in its relative valuation, which is a method of valuing INmune Bio by comparing valuation metrics with similar companies.
Peers
INmune Bio Related Equities
| CUE | Cue Biopharma | 6.62 | ||||
| INAB | In8bio | 4.00 | ||||
| SAVA | Cassava Sciences | 3.03 | ||||
| DRMA | Dermata Therapeutics | 2.50 | ||||
| AVTE | Aerovate Therapeutics | 1.55 | ||||
| TCRX | Tscan Therapeutics | 0.39 | ||||
| ANIX | Anixa Biosciences | 2.00 | ||||
| ANTX | AN2 Therapeutics | 2.56 | ||||
| AVXL | Anavex Life | 3.13 | ||||
| ANEB | Anebulo Pharmaceuticals | 3.14 | ||||
| BIVI | Biovie | 3.47 | ||||
| PYPD | PolyPid | 4.35 | ||||
| CGTX | Cognition Therapeutics | 6.49 |
Complementary Tools for INmune Stock analysis
When running INmune Bio's price analysis, check to measure INmune Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy INmune Bio is operating at the current time. Most of INmune Bio's value examination focuses on studying past and present price action to predict the probability of INmune Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move INmune Bio's price. Additionally, you may evaluate how the addition of INmune Bio to your portfolios can decrease your overall portfolio volatility.
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like |